- Home
- CMA vs LEGN Comparison
CMA vs LEGN Comparison
Compare CMA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- LEGN
- Stock Information
- Founded
- CMA 1849
- LEGN 2014
- Country
- CMA United States
- LEGN United States
- Employees
- CMA N/A
- LEGN N/A
- Industry
- CMA Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- LEGN Health Care
- Exchange
- CMA Nasdaq
- LEGN Nasdaq
- Market Cap
- CMA 6.9B
- LEGN 7.0B
- IPO Year
- CMA N/A
- LEGN 2020
- Fundamental
- Price
- CMA $52.95
- LEGN $32.80
- Analyst Decision
- CMA Hold
- LEGN Strong Buy
- Analyst Count
- CMA 22
- LEGN 12
- Target Price
- CMA $66.86
- LEGN $79.00
- AVG Volume (30 Days)
- CMA 2.4M
- LEGN 1.6M
- Earning Date
- CMA 04-21-2025
- LEGN 05-12-2025
- Dividend Yield
- CMA 5.41%
- LEGN N/A
- EPS Growth
- CMA N/A
- LEGN N/A
- EPS
- CMA 5.02
- LEGN N/A
- Revenue
- CMA $3,195,000,000.00
- LEGN $627,241,000.00
- Revenue This Year
- CMA $7.95
- LEGN $66.92
- Revenue Next Year
- CMA $3.39
- LEGN $51.77
- P/E Ratio
- CMA $10.55
- LEGN N/A
- Revenue Growth
- CMA N/A
- LEGN 119.97
- 52 Week Low
- CMA $45.32
- LEGN $29.27
- 52 Week High
- CMA $73.45
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CMA 41.14
- LEGN 45.92
- Support Level
- CMA $51.90
- LEGN $29.27
- Resistance Level
- CMA $53.89
- LEGN $35.11
- Average True Range (ATR)
- CMA 2.86
- LEGN 1.89
- MACD
- CMA 0.01
- LEGN 0.16
- Stochastic Oscillator
- CMA 42.90
- LEGN 60.48
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.